Cellular senescence in cancer treatment: friend or foe?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 14722606.
- Also identified by PMC identifier 311442.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of senescence is a beneficial or, rather, a detrimental consequence of the therapeutic intervention.
Medical subject headings
- Cellular Senescence
- Neoplasms